The log-rank test indicated a significant association of mRNA levels with overall survival (OS) of lung cancer patients (P < 0.05), and the TIMELESS, RORA, PER2, and CRY2 expressions were significantly correlated with progression-free survival (PFS) in lung cancer patients (P < 0.05). This evidence concerns the gene PER2 and lung cancer.